VYJUVEK continues global expansion with strong U.S. and Japan launches, robust pricing, and a solid financial position. Pipeline progress includes blinded ocular DEB and NK studies with clean safety profiles, and additional programs in CF, AATD, oncology, and Hailey-Hailey disease.
Based on Krystal Biotech, Inc. [KRYS] Evercore ISI 8th Annual HealthCONx Conference Audio Transcript — Dec. 3 2025
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
